Antibodies to opgl

Abstract

Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.

1 - 29 . (canceled) 
     
     
         30 . An antibody; comprising a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467, and the light chain comprises the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235. 
     
     
         31 . An antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises the variable region and the constant region of SEQ ID NO:2 having one carboxy-terminal amino acid deletion, and wherein the light chain comprises the variable region and the constant region of SEQ ID NO:4 having one carboxy-terminal amino acid deletion. 
     
     
         32 . An antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises the variable region and the constant region of SEQ ID NO:2 having one carboxy-terminal amino acid deletion; and wherein the light chain comprises the variable region and the constant region of SEQ ID NO:4. 
     
     
         33 . An antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises a variable region comprising the amino acid sequence as forth in SEQ ID NO: 13 and a light chain, wherein the antibody binds to an osteoprotegerin ligand (OPGL). 
     
     
         34 . The antibody of  claim 33 , wherein the antibody inhibits binding of OPGL to an osteoclast differentiation and activation receptor (ODAR). 
     
     
         35 . An antibody, comprising a heavy chain and a light chain, wherein the light chain comprises a variable region comprising the amino acid sequence as set forth in SEQ ID NO: 14, and a heavy chain, wherein the antibody binds to an osteoprotegerin ligand (OPGL). 
     
     
         36 . The antibody of  claim 35 , wherein the antibody inhibits binding of OPGL to an osteoclast differentiation and activation receptor (ODAR). 
     
     
         37 . A pharmaceutical composition comprising the antibody of any one of  claims 30 ,  31 , and  32 . 
     
     
         38 . The pharmaceutical composition of  claim 37 , wherein the composition comprises an acetate buffer. 
     
     
         39 . The pharmaceutical composition of  claim 37 , wherein the composition comprises polysorbate. 
     
     
         40 . The pharmaceutical composition of  claim 37 , wherein the composition comprises sorbitol. 
     
     
         41 . The pharmaceutical composition of  claim 37 , wherein the composition comprises acetate and sorbitol. 
     
     
         42 . The pharmaceutical composition of  claim 37 , wherein the composition is contained in a prefilled syringe. 
     
     
         43 . The pharmaceutical composition of  claim 38 , wherein the composition is contained in a prefilled syringe. 
     
     
         44 . The pharmaceutical composition of  claim 39 , wherein the composition is contained in a prefilled syringe. 
     
     
         45 . The pharmaceutical composition of  claim 40 , wherein the composition is contained in a prefilled syringe. 
     
     
         46 . The pharmaceutical composition of  claim 41 , wherein the composition is contained in a prefilled syringe. 
     
     
         47 . The pharmaceutical composition of  claim 37 , wherein the composition is in unit dose form. 
     
     
         48 . A pharmaceutical composition comprising the antibody of any one of  claims 33 ,  34 ,  35 , and  36 .